Transplant Immunosuppression & Complications

📋 Key Information Summary

📋

Kidney transplant immunosuppression follows a universal triple-drug regimen: a calcineurin inhibitor (tacrolimus), an anti-metabolite (mycophenolate), and corticosteroids (prednisolone).
Induction therapy with basiliximab (IL-2 receptor antagonist) is standard for low–moderate immunological risk; anti-thymocyte globulin (thymoglobulin) is reserved for high-risk recipients (high PRA, re-transplant, young ATSI donors).
Tacrolimus trough targets are 8–12 ng/mL in the first 3 months, 5–8 ng/mL from 3–12 months, and 4–6 ng/mL thereafter, adjusted for rejection history and concurrent agents.
Mycophenolate mofetil (MMF) is dosed at 1 g BD for adults; target MPA AUC₀₋₁₂ₕ 30–60 mg·h/L where therapeutic drug monitoring is available.
Prednisolone is tapered from 20–25 mg/day to 5 mg/day by month 3–6; steroid withdrawal is considered only in selected low-risk patients under specialist supervision.
BK virus nephropathy (BKVN) occurs in 1–10% of recipients; screen plasma BK viral load monthly for the first 6–12 months, then quarterly for 2 years.
CMV disease is the most common post-transplant viral infection; D+/R− mismatch carries the highest risk — valganciclovir prophylaxis for 3–6 months is mandatory.
Post-transplant malignancy risk is 3–5× the general population; PTLD occurs in 1–3%, most commonly EBV-driven B-cell lymphoma within the first year.
Reduce immunosuppression in a stepwise fashion for BKVN (first MMF, then tacrolimus) and for malignancy (minimise CNIs, consider mTOR inhibitor conversion).
Aboriginal and Torres Strait Islander recipients have higher rates of CMV, BK, and late rejection; culturally safe follow-up and enhanced viral monitoring are essential.
All transplant medications require PBS Authority approval; ensure continuity of supply through hospital outpatient pharmacy or shared-care agreements with community pharmacy.
Lifelong nephrology follow-up with protocol biopsies at 3 and 12 months detects subclinical rejection and guides immunosuppression optimisation.

Introduction & Australian Epidemiology

Post-transplant immunosuppression is the cornerstone of graft survival following renal transplantation. The fundamental strategy involves a universal triple-drug regimen — comprising a calcineurin inhibitor (CNI), an anti-metabolite, and corticosteroids — designed to prevent T-cell–mediated acute rejection while minimising the long-term consequences of over-immunosuppression, including infection, malignancy, nephrotoxicity, and metabolic complications.

In Australia, over 1,400 kidney transplants are performed annually, with the majority from deceased donors. Five-year graft survival exceeds 90% for living-donor and 85% for deceased-donor recipients. Despite these excellent outcomes, managing the balance between rejection prevention and minimising adverse effects remains a lifelong clinical challenge. The ANZDATA Registry reports acute rejection rates of 10–15% in the first year, declining with modern induction and maintenance protocols.

Australian practice is guided by The Transplantation Society of Australia and New Zealand (TSANZ) consensus statements, the Australian Kidney Trials Network (AKTN) trial data, and adapted international guidelines from KDIGO and ERA-EDTA. This guideline provides a comprehensive framework for induction, maintenance, and complication management, with emphasis on Australian drug availability, PBS considerations, and health equity for Aboriginal and Torres Strait Islander peoples.

⚠️

Therapeutic drug monitoring (TDM) is essential for tacrolimus, sirolimus, and cyclosporin. Ensure trough levels are drawn at consistent times relative to dosing (12 hours post-dose for BD regimens) and report to the transplant centre within 24 hours.

Induction Therapy — Basiliximab & Thymoglobulin

Induction therapy is administered peri-operatively to provide intense initial immunosuppression during the highest risk period for acute rejection. The choice of agent is stratified by immunological risk.

Immunological Risk Stratification

Low Risk

Basiliximab

First transplant, PRA <20%, non-sensitised, living related donor, no donor-specific antibodies (DSA).

Setting: Standard ward

Moderate Risk

Basiliximab ± consideration of ATG

PRA 20–80%, prolonged cold ischaemia >24 h, older deceased donor, second transplant with stable course.

Setting: Specialist discussion

High Risk

Thymoglobulin (rATG)

PRA >80%, positive crossmatch (desensitised), re-transplant after rejection-related graft loss, young ATSI donor, DSA positive.

Setting: Transplant centre only

Basiliximab (Simulect®)

Basiliximab is a chimeric monoclonal antibody targeting the IL-2 receptor alpha chain (CD25) on activated T-cells. It provides selective immunosuppression without broad lymphocyte depletion.

💊

Basiliximab

Simulect® · Novartis · IL-2 receptor antagonist

Adult dose 20 mg IV on Day 0 (pre-reperfusion) and Day 4

Paediatric dose <35 kg: 10 mg IV × 2 doses; ≥35 kg: 20 mg IV × 2 doses

Route Intravenous infusion over 20–30 minutes

Renal adjustment None required

Hepatic adjustment None required

PBS status 🔒 Authority Required — Specialist

Anti-Thymocyte Globulin — Rabbit (Thymoglobulin®)

Rabbit ATG (rATG) is a polyclonal antibody preparation that causes profound T-cell depletion through complement-dependent lysis and apoptosis. It provides powerful rejection prophylaxis but carries greater infectious and malignancy risk.

💊

Anti-thymocyte globulin (rabbit)

Thymoglobulin® · Sanofi · Polyclonal antibody

Adult dose 1.5 mg/kg IV daily × 3–5 doses, starting intra-operatively or Day 0–1. Total induction dose: 4.5–7.5 mg/kg.

Paediatric dose 1.5 mg/kg IV daily × 3–5 doses (same as adult, weight-based)

Route IV infusion via central line over ≥6 hours (first dose); ≥4 hours (subsequent)

Key precautions Pre-medicate with paracetamol, promethazine, corticosteroids. Monitor FBC daily; CMV/PCP prophylaxis mandatory.

Renal adjustment None required

PBS status 🔒 Authority Required — Specialist

⚠️

ATG and CMV risk: Recipients receiving thymoglobulin induction require extended CMV prophylaxis (typically 6 months of valganciclovir) regardless of D/R CMV serostatus, due to profound lymphocyte depletion.

Maintenance Immunosuppression — Tacrolimus, MMF & Prednisolone

The standard Australian maintenance triple-therapy regimen consists of tacrolimus (CNI), mycophenolate mofetil (anti-metabolite), and prednisolone (corticosteroid). This combination is used in >85% of Australian kidney transplant recipients.

Tacrolimus (Prograf® / FK-506)

💊

Tacrolimus

Prograf® · Generic available · Calcineurin inhibitor

Adult starting dose 0.1–0.2 mg/kg/day PO divided BD (start Day 0–1). Adjust by trough level.

Paediatric dose 0.15–0.3 mg/kg/day PO divided BD (children often require higher mg/kg due to increased clearance)

Trough targets 0–3 months: 8–12 ng/mL · 3–12 months: 5–8 ng/mL · >12 months: 4–6 ng/mL

Key interactions ↑ with azoles, macrolides, grapefruit, diltiazem. ↓ with rifampicin, phenytoin, St John's wort.

Renal adjustment Dose by trough level — inherently nephrotoxic; monitor serum creatinine closely

Hepatic adjustment Reduce dose 50% in severe hepatic impairment (Child-Pugh C)

PBS status ✔ PBS General Benefit

Mycophenolate Mofetil (CellCept® / Myfortic®)

💊

Mycophenolate mofetil

CellCept® · Myfortic® (enteric-coated) · Anti-metabolite

Adult dose 1 g PO/IV BD (CellCept) or 720 mg PO BD (Myfortic). Start pre-operatively or Day 0.

Paediatric dose 600 mg/m² PO BD (max 1 g BD for BSA ≥1.5 m²)

TDM (if available) MPA AUC₀₋₁₂ₕ 30–60 mg·h/L (limited availability in Australia; trough monitoring MPA >1.5 mg/L as surrogate)

Key side effects GI disturbance (diarrhoea, nausea), leucopenia, anaemia. Avoid with severe GI disease.

Renal adjustment No dose change in renal impairment; avoid IV formulation in CrCl <25 mL/min (citrate vehicle)

PBS status ✔ PBS General Benefit

Prednisolone

💊

Prednisolone

Solone® · Panafcortelone® · Corticosteroid

Induction dose 500 mg–1 g IV methylprednisolone on Day 0, then taper

Maintenance taper 20–25 mg/day Week 1 → 15 mg/day Week 2–4 → 10 mg/day Month 2–3 → 5 mg/day by Month 3–6

Long-term target 5 mg/day indefinitely in most patients; withdrawal considered only in selected low-risk cohort

Paediatric dose Same tapering strategy; weight-based (0.3–0.5 mg/kg/day maintenance)

Key monitoring Fasting glucose, HbA1c, lipids, BMD (DEXA at 1 year), ophthalmology review

PBS status ✔ PBS General Benefit

Trough Level Monitoring — Tacrolimus

Time Period	Target Trough (ng/mL)	Monitoring Frequency	Notes
Week 1–2	10–15	Daily	Initiation phase; check on Day 3 then daily until stable
Month 1–3	8–12	Weekly → fortnightly	Highest rejection risk period
Month 3–12	5–8	Monthly	Reduce if CMV/BK detected
>12 months	4–6	Every 2–3 months	Lower targets reduce nephrotoxicity and malignancy risk

✅

Generic substitution: Generic tacrolimus is PBS-listed and bioequivalent to Prograf®. In Australia, brand-to-generic switches require repeat trough monitoring at 1–2 weeks post-switch to confirm stable levels.

BK Nephropathy & CMV After Transplant

BK Virus Nephropathy (BKVN)

BK polyomavirus reactivation is a significant cause of graft dysfunction, occurring in 1–10% of renal transplant recipients. BKVN — histologically confirmed polyomavirus-associated nephropathy (PVAN) — carries a 10–50% graft loss risk if not identified early. There is no proven antiviral therapy; management centres on immunosuppression reduction.

BK Screening Protocol (Australian Standard)

Essential Plasma BK viral load (quantitative PCR) Monthly × 6 months, then 3-monthly × 2 years, then annually. Report in copies/mL.

Available Urine decoy cells (cytology) Low sensitivity; useful as adjunct. Positive predictive value ~30% for BKVN.

Biopsy indicated For-cause renal biopsy (SV40 immunohistochemistry) Indicated when plasma BK viral load >10,000 copies/mL or rising creatinine with any detectable viraemia.

BKVN Management Algorithm

1

Detect — Plasma BK >10,000 copies/mL

Confirm with repeat PCR within 2 weeks. Ensure adequate hydration. Review overall immunosuppression intensity.

2

Reduce — First MMF, then tacrolimus

Reduce MMF by 50% (e.g., 1 g BD → 500 mg BD). If viraemia persists at 4 weeks, reduce tacrolimus trough to 4–6 ng/mL. Aim for overall 30–50% reduction in immunosuppression.

3

Monitor — Weekly viral load until clearance

Expect 1–2 log₁₀ reduction within 4–8 weeks. Monitor serum creatinine fortnightly. Biopsy if graft function deteriorates.

4

Escalate — Refractory BKVN

Consider conversion from tacrolimus to low-dose cyclosporin (trough 100–150 ng/mL). IVIG (2 g/kg) has anecdotal benefit. Refer to transplant nephrology.

🚨

Do NOT use antiviral agents (cidofovir, leflunomide, fluoroquinolones) as first-line therapy for BKVN. No randomised controlled trial has demonstrated benefit. Immunosuppression reduction remains the only evidence-based strategy. Leflunomide carries significant hepatotoxicity risk.

Cytomegalovirus (CMV) Disease

CMV is the most clinically important viral infection post-transplant, affecting 8–32% of renal recipients. It causes direct disease (fever, pneumonitis, colitis, retinitis, hepatitis) and indirect effects (acute rejection, graft dysfunction, cardiovascular events, increased mortality).

Risk Stratification by CMV Serostatus

Donor / Recipient	Risk Category	Prophylaxis Duration	Agent
D+ / R−	Highest	6 months	Valganciclovir
D+ / R+	High	3–6 months	Valganciclovir
D− / R+	Moderate	3 months	Valganciclovir
D− / R−	Low	Consider prophylaxis if ATG induction used	Valaciclovir or valganciclovir

💊

Valganciclovir

Valcyte® · Roche · Antiviral (CMV)

Prophylaxis dose 900 mg PO once daily (adjusted for renal function)

Treatment dose 900 mg PO BD × 21 days (induction), then 900 mg PO daily (maintenance)

Renal adjustment (prophylaxis) CrCl 40–59: 450 mg daily · CrCl 25–39: 450 mg alternate days · CrCl 10–24: 450 mg twice weekly

Key side effects Neutropenia (20–30%), thrombocytopenia, anaemia. Monitor FBC weekly × 1 month, then fortnightly.

PBS status ⚠️ PBS Restricted Benefit — Specialist

CMV Treatment (Active Disease)

CMV disease requires IV ganciclovir (5 mg/kg IV BD, renal adjusted) for severe or tissue-invasive disease, followed by oral valganciclovir. Quantitative CMV PCR should be monitored weekly during treatment and fortnightly for 3 months post-clearance. Reduce immunosuppression concurrently — typically stop MMF first, then reduce tacrolimus.

⚠️

CMV resistance: Suspect UL97 or UL54 mutations if viral load fails to decrease by >1 log₁₀ after 2 weeks of adequate-dose therapy. Request genotypic resistance testing (available through reference laboratories such as Westmead Hospital Virology). Switch to foscarnet (60 mg/kg IV TDS, renal adjusted) if confirmed.

Post-transplant Malignancy & PTLD

Post-transplant malignancy is a leading cause of late graft loss and death in kidney transplant recipients. The cumulative incidence is 20–30% at 10 years — approximately 3–5 times that of the general population. The ANZDATA Registry identifies cancer as the second leading cause of death with a functioning graft (after cardiovascular disease).

Cancer Risk by Type

Cancer Type	SIR vs General Population	Median Onset	Key Risk Factor
Non-melanoma skin cancer (NMSC)	5–10×	>5 years	UV exposure, azathioprine history, fair skin
PTLD	20–50×	6–12 months	EBV D+/R−, ATG induction, high CNI levels
Kaposi sarcoma	50–100×	1–2 years	HHV-8, high immunosuppression
Colorectal cancer	2–3×	>5 years	Age, IBD history
Anogenital cancer	5–15×	>3 years	HPV infection
Thyroid cancer	3–5×	Variable	Unknown (increased surveillance may contribute)

Post-Transplant Lymphoproliferative Disorder (PTLD)

PTLD encompasses a spectrum of lymphoid proliferations ranging from benign polyclonal hyperplasia to aggressive monomorphic lymphoma. It occurs in 1–3% of kidney transplant recipients, with 80% being EBV-driven.

WHO Classification (Simplified)

Early Lesions

Plasmacytic hyperplasia / Infectious mononucleosis-like

Polyclonal, EBV+. Often self-limiting with immunosuppression reduction alone.

Setting: Transplant outpatient

Polymorphic

Polymorphic PTLD

Destructive lesion with mixed lymphoid infiltrate. May respond to immunosuppression reduction ± rituximab.

Setting: Haematology + transplant

Monomorphic

Monomorphic PTLD (DLBCL, Burkitt-like)

Aggressive B-cell lymphoma. Requires immunochemotherapy (R-CHOP). 5-year survival 50–70%.

Setting: Haematology oncology

PTLD Management Strategy

1

Reduce Immunosuppression (RIS)

First-line for all PTLD. Stop MMF/azathioprine. Reduce tacrolimus trough to 3–5 ng/mL (or 50% reduction). Goal: restore some immune surveillance against EBV while accepting rejection risk (10–20%).

2

Rituximab (CD20+ tumours)

375 mg/m² IV weekly × 4 doses. For CD20+ polymorphic or monomorphic PTLD not responding to RIS at 2–4 weeks. PBS Authority Required.

3

R-CHOP Chemotherapy

For monomorphic PTLD refractory to rituximab alone. Rituximab + cyclophosphamide + doxorubicin + vincristine + prednisolone. Administered by haematology oncology.

4

Surgical Resection / Radiotherapy

For localised disease (e.g., GI tract PTLD). Adjuvant to systemic therapy.

⚠️

EBV monitoring: EBV DNA PCR surveillance is recommended for high-risk patients (D+/R− mismatch, paediatric recipients, ATG induction). Quantitative EBV PCR monthly × 6 months, then quarterly. Rising EBV titres should prompt pre-emptive immunosuppression reduction before clinical PTLD develops.

NMSC Prevention

Non-melanoma skin cancer (NMSC) is the most common post-transplant malignancy in Australia, reflecting high UV exposure. All recipients require:

Annual full skin examination by a dermatologist or trained GP (6-monthly if history of NMSC)
Strict sun protection: SPF 50+ broad-spectrum sunscreen, UPF 50+ clothing, hats, shade avoidance
Nicotinamide 500 mg PO BD — shown to reduce new NMSC by 23% in high-risk individuals (ONTRAC trial)
Consider switching azathioprine to MMF (azathioprine increases UV mutagenesis)
Consider mTOR inhibitor conversion (sirolimus/everolimus) in patients with recurrent/metastatic SCC — associated with reduced NMSC incidence

Nicotinamide is available over the counter in Australia and is PBS-listed for Pellagra only; off-label use for NMSC prevention is at patient cost (~/month).

Special Populations

🤰 Pregnancy

Tacrolimus Safe in pregnancy (Category C). Continue at pre-pregnancy dose. Trough levels may drop due to increased volume of distribution — monitor fortnightly. Crosses placenta but no proven teratogenicity.

Mycophenolate CONTRAINDICATED — Category D. Teratogenic (microtia, cleft lip/palate, limb defects). Discontinue ≥6 weeks before conception. Switch to azathioprine 1–2 mg/kg/day.

Prednisolone Safe in pregnancy. Continue at lowest effective dose. Monitor for gestational diabetes.

Sirolimus / Everolimus CONTRAINDICATED — Category D. Discontinue ≥12 weeks before planned pregnancy.

👶 Paediatrics

Tacrolimus Higher mg/kg dosing required (0.15–0.3 mg/kg/day) due to increased clearance. Trough targets identical to adults. Engraftment syndrome more common in paediatric recipients — monitor closely in first 48 hours.

MMF 600 mg/m² BD. Oral suspension available. GI side effects more common — consider enteric-coated mycophenolate sodium (Myfortic®).

Growth Steroid minimisation protocols prioritised to optimise linear growth. Deflazacort not available in Australia. Monitor bone age and IGF-1 annually.

EBV / PTLD Children are more commonly EBV-naïve pre-transplant; D+/R− mismatch is common. EBV PCR monitoring mandatory. PTLD incidence 3–5× higher in paediatric recipients.

👴 Elderly (>65 years)

Immunosuppression intensity Consider reduced-dose protocols (lower trough targets: tacrolimus 4–6 ng/mL from 3 months). Basiliximab preferred over ATG. Higher infection and malignancy risk mandates lower overall immunosuppression.

Polypharmacy Increased drug interaction risk. Review medications quarterly. Avoid NSAIDs, minimise nephrotoxins. Screen for falls (steroid myopathy, osteoporosis).

🩺 Renal Impairment (Graft Dysfunction)

Tacrolimus No dose adjustment by eGFR — dosing guided by trough. However, CNI nephrotoxicity may require conversion to belatacept or mTOR inhibitor in chronic graft dysfunction.

Valganciclovir Requires renal dose adjustment as per renal function tables above. Dose based on CrCl (Cockcroft-Gault).

🫁 Hepatic Impairment

Tacrolimus Reduce dose by 50% in severe hepatic impairment (Child-Pugh C). Metabolised by CYP3A4/5 — reduced hepatic clearance leads to higher trough levels. Monitor trough closely.

MMF MPA is hepatically metabolised (glucuronidation). Hepatic impairment may increase free MPA. Monitor for toxicity (leucopenia, GI symptoms).

🦠 Immunocompromised / Re-transplant

Induction Re-transplant after rejection-related graft loss: ATG induction recommended. Sensitised patients may require desensitisation with IVIG/plasmapheresis pre-transplant.

Monitoring Enhanced viral surveillance (CMV, BK, EBV) due to cumulative immunosuppression exposure. Consider donor-derived cell-free DNA (dd-cfDNA) testing where available.

Aboriginal and Torres Strait Islander Health Considerations

Aboriginal and Torres Strait Islander Health

Epidemiological burden

Aboriginal and Torres Strait Islander peoples experience kidney failure at 7–8 times the rate of non-Indigenous Australians. They are more likely to receive a transplant from a deceased donor and face longer wait times. ATSI recipients constitute ~5% of transplant recipients but experience higher rates of late rejection and graft loss.

Infection risk

Higher prevalence of CMV seropositivity in remote communities (D+/R+ is common). BK viraemia rates are comparable to non-Indigenous recipients but may present later due to access barriers. Community-acquired MRSA (CA-MRSA) is more prevalent in remote communities — consider this when treating post-transplant skin/soft tissue infections.

Medication access

PBS Authority Required medications (e.g., valganciclovir, thymoglobulin) require specialist prescribing. Remote communities may face pharmacy supply chain delays. Coordinate 2–4 week medication supplies through hospital outpatient pharmacy with community pharmacy continuity. Ensure patients on closing-the-gap PBS co-payment have no out-of-pocket costs.

Follow-up adherence

Geographic remoteness creates barriers to 3-monthly transplant clinic attendance. Utilise telehealth (MBS item 91822/91823) and community health worker support. Partner with Aboriginal Medical Services (AMS) for trough level blood collection and basic pathology monitoring.

Cultural safety

Engage Aboriginal Health Workers and Liaison Officers in medication education, particularly for complex regimens. Respect cultural obligations around Sorry Business and ensure flexible appointment scheduling. Use plain language and visual medication aids.

Malignancy screening

NMSC rates are lower in darker-skinned ATSI individuals, but melanoma and internal malignancies remain important. Ensure colonoscopy and age-appropriate cancer screening is maintained. Coordinate with local health services to reduce barriers to preventive care.

📚 References

1. Kidney Disease: Improving Global Outcomes (KDIGO). KDIGO Clinical Practice Guideline on the Evaluation and Management of Candidates for Kidney Transplantation. Transplantation. 2020;104(4S1):S1–S103.
2. Chadban SJ, Ahn C, Axelrod DA, et al. KDIGO Clinical Practice Guideline on the Evaluation and Management of Candidates for Kidney Transplantation. Kidney Int Suppl. 2020;10(2):e1–e98.
3. Russ GR, Lim WH, Chapman JR. Long-term outcomes of kidney transplantation. In: Morris PJ, Knechtle SJ, eds. Kidney Transplantation: Principles and Practice. 8th ed. Elsevier; 2020:521–542.
4. Australia and New Zealand Dialysis and Transplant (ANZDATA) Registry. 46th Annual Report 2023. Adelaide: SA Health and Medical Research Institute; 2023. Available from: www.anzdata.org.au
5. The Transplantation Society of Australia and New Zealand (TSANZ). Guidelines for the Prevention and Management of CMV Disease After Solid Organ Transplantation. Transplantation. 2021;105(5):945–960.
6. Hirsch HH, Randhawa PS. BK polyomavirus in solid organ transplantation — guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. Clin Transplant. 2019;33(9):e13528.
7. Allen UD, Preiksaitis JK. Post-transplant lymphoproliferative disorders and Epstein-Barr virus: guidelines from the AST Infectious Diseases Community of Practice. Clin Transplant. 2019;33(9):e13652.
8. Chapman JR, Webster AC, Wong G. Cancer in the transplant recipient. Cold Spring Harb Perspect Med. 2013;3(7):a015677.
9. Chen AC, Martin AJ, Choy B, et al. A Phase 3 randomized trial of nicotinamide for skin-cancer chemoprevention (ONTRAC trial). N Engl J Med. 2015;373(17):1618–1626.
10. Australian Institute of Health and Welfare (AIHW). Chronic kidney disease: Aboriginal and Torres Strait Islander people. Cat. no. PHE 248. Canberra: AIHW; 2022.
11. McDonald SP, Russ GR. Kidney transplant survival in Indigenous Australians: ANZDATA analysis. Nephrology. 2005;10(Suppl 1):A1–A156.
12. Kidney Health Australia. Caring for Australasians with Kidney Disease — Clinical Practice Guidelines for Post-transplant Care. Melbourne: Kidney Health Australia; 2023.
13. National Health and Medical Research Council (NHMRC). Australian Guidelines to Reduce Health Risks from Drinking Alcohol. Canberra: NHMRC; 2020.
14. Dantal J, Pohanka E. Malignancies after renal transplantation: an unsolved problem. Nephrol Dial Transplant. 2018;33(Suppl 1):i1–i8.